Publications by authors named "Amerio P"

Objective: Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.

Methods: An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline.

View Article and Find Full Text PDF

the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98.

View Article and Find Full Text PDF

This article presents a case study of a novel modification of the A-T flap, known as "Sorting Hat" flap, employed in dermatologic surgery for facial reconstruction. In the treatment of an 89-year-old male's squamous cell carcinoma lesion on the forehead, the "Sorting Hat" flap, introduced as an innovative alternative, eliminates the need for Burrow triangles and relies on flap shape for inconspicuous scarring and favorable cosmetic outcomes.

View Article and Find Full Text PDF

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients' quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis of the disease led to a new era for the treatment of AD.

View Article and Find Full Text PDF

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis.

View Article and Find Full Text PDF
Article Synopsis
  • Prurigo nodularis (PN) is a chronic skin condition causing severe itching, and this study aimed to assess its impact on healthcare costs and resource use in Italy.
  • The research analyzed data from 295 hospitalized PN patients and matched them with 590 non-PN individuals, revealing significant differences in comorbidities and healthcare resource consumption over a one-year follow-up period.
  • PN patients had much higher healthcare costs, averaging €3847 compared to €711 for non-PN controls, primarily due to increased medication prescriptions, hospitalizations, and outpatient services.
View Article and Find Full Text PDF
Article Synopsis
  • * Treatment methods for HS include a mix of medical therapies (like antibiotics and biologics) and surgical options, though many patients still experience high rates of recurrence and progression despite these treatments.
  • * A recent meeting of Italian HS experts focused on improving treatment strategies, emphasizing the importance of integrating biologic therapy with surgical options, and identifying ten key areas that need further exploration to optimize patient care.
View Article and Find Full Text PDF

The comparison between conscious and unconscious perception is a cornerstone of consciousness science. However, most studies reporting above-chance discrimination of unseen stimuli do not control for criterion biases when assessing awareness. We tested whether observers can discriminate subjectively invisible offsets of Vernier stimuli when visibility is probed using a bias-free task.

View Article and Find Full Text PDF

Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading to poor quality of life, especially in patients with moderate-to-severe disease. Since atopic and non-atopic comorbidities can further worsen the disease course, accurate establishment of the patient's individual intrinsic risk profile and needs is crucial and may help in guiding the selection of the best treatment option.

View Article and Find Full Text PDF
Article Synopsis
  • A new guideline for atopic eczema was published in two parts in August and September 2022, based on the EuroGuiDerm standards, following extensive consensus conferences with experts from twelve European countries.
  • The guideline incorporates recent evidence on new systemic medications, with an update released in October 2022.
  • Italian dermatological societies adapted the original EuroGuiDerm guideline for the Italian healthcare context, adding specific notes to highlight regulations and recommendations from the Italian Ministry of Health and regional authorities.
View Article and Find Full Text PDF

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual.

View Article and Find Full Text PDF
Article Synopsis
  • - SIDeMaST developed guidelines for treating chronic plaque psoriasis and adapted them for the Italian healthcare system, aiming to provide a dependable resource for doctors treating atopic dermatitis patients in Italy.
  • - The guideline follows the EuroGuiDerm Manual and was created with the input of 29 experts from 12 European countries, involving four consensus conferences held between December 2020 and July 2021.
  • - It includes comprehensive information on systemic therapies, discussing conventional immunosuppressants, biologics, and Janus kinase inhibitors, while the second part will focus on factors like diet, immunotherapy, and considerations for special patient groups.
View Article and Find Full Text PDF

Venous leg ulcers are one of the most common nonhealing conditions and represent an important clinical problem. The application of pulsed radiofrequency electromagnetic fields (PRF-EMFs), already applied for pain, inflammation, and new tissue formation, can represent a promising approach for venous leg ulcer amelioration. This study aims to evaluate the effect of PRF-EMF exposure on the inflammatory, antioxidant, cell proliferation, and wound healing characteristics of human primary dermal fibroblasts collected from venous leg ulcer patients.

View Article and Find Full Text PDF

Creating an integrated design space can be successful only if researchers agree on how to define and measure a certain phenomenon of interest. Adversarial collaborations and mathematical modeling can aid in reaching the necessary level of agreement when researchers depart from different theoretical perspectives.

View Article and Find Full Text PDF
Article Synopsis
  • * A study involving 118 adults with moderate-to-severe AD found that over half experienced sleep issues, severe itching, and frequent flare-ups, affecting their daily functioning.
  • * Many patients reported significant disease impact on their lives, with around 37.3% indicating severe effects from AD, while one in four felt their current treatment was insufficient.
View Article and Find Full Text PDF

A 12-year-old boy affected by severe combined immunodeficiency due to a heterozygous variant in the CARD domain of CARD11, c.169G>A; p.Glu57Lys, developed severe atopic dermatitis and alopecia areata.

View Article and Find Full Text PDF

Background: Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults. However, limited research has been conducted on gender differences in AD.

Objectives: This study aimed to assess gender differences in adult AD patients, focusing on demographic and clinical features, comorbidities and treatment approaches.

View Article and Find Full Text PDF

Hidradenitis suppurativa (HS) is considered a post-pubertal disease; however, earlier onset is not infrequent. The burden of HS on the female population is very relevant, and early identification might reduce the quality of life impairment and improve the therapeutic approach. In this study, we investigated clinical biomarkers of HS that could impact the management of patients affected by HS.

View Article and Find Full Text PDF

Background: The Pacman flap is a modified V-Y advancement flap that showed to be versatile in repairing surgical and non-surgical wounds. Indeed, this flap has been used in any anatomical localization, except for the scalp, where its use has not been reported. Moreover, the versatility of the Pacman flap can be enhanced by applying simple modifications to its original design.

View Article and Find Full Text PDF
Article Synopsis
  • Immunodeficiency with thymoma, first described by R.A. Good in 1954, involves low levels of antibodies (hypogammaglobulinemia) and a thymoma, leading to frequent infections from various pathogens.
  • The syndrome is also associated with autoimmune diseases like pure red cell aplasia and other blood disorders, alongside conditions such as erosive lichen planus.
  • The article discusses a specific case that showcases these symptoms and presents findings on autoantibodies related to cytokines, while highlighting the ongoing research and unanswered questions about this rare syndrome.
View Article and Find Full Text PDF

Background: After decades of use, methotrexate displays an established safety and efficacy profile in both in-hospital and outpatient settings. Despite its widespread use, there is surprisingly little clinical evidence to guide daily practice with methotrexate in dermatology.

Objectives: To provide guidance for clinicians in daily practice for areas in which there is limited guidance.

View Article and Find Full Text PDF